Who we are

We are a family foundation driven by the conviction that the rigorous scientific process of establishing proof of principle and clinical evidence can be applied to novel benign approaches for cancer.

How we work

Benefiting from its status as an independent foundation, Seerave is building diverse partnerships and supporting efforts which bring novel benign approaches to cancer patients as quickly as possible. To speed up progress and reduce duplication, Seerave believes that cross-disciplinary and cross-border collaboration from “bench to bedside” is necessary. This may include academic researchers, clinicians, young startups as well as ventures from different fields of life sciences and technology. We act as a catalyst to join the dots between different endeavors.

I m m u n e s y s t e m C a n c e r a n d o t h e r d i s e a s e s ( e . g . n u t r i t i o n ) M i c r o b i o m e N o v e l b e n i g n a p p r o a c h e s


David Rees


Elisabeth Rees

Chief Operating Officer

Manuel Fankhauser, PhD

Chief Scientific Officer

Sandra Sulser, PhD

Senior Scientific Project Manager

Laura Mählmann, PhD

Scientific Project Manager

Rossella Fontana, PhD

Bioengineering Project Manager



The Seerave Foundation aspires to broaden and enhance the Standard of Care for cancer patients. We aim to do this by augmenting current cancer therapies with novel, benign and diverse approaches. These will be evidence-based, lead to clinically proven benefits for patients and also contribute to more sustainable health care systems. Our initial focus is on the nutrition, microbiome and immune system axis.


We will build partnerships and support efforts to:

Better understand the basic biology and interplay of nutrition, microbiome, metabolites, immune system and cancer.

Establish scientific proof of principle that novel approaches are efficacious in pre-clinical settings of cancer research, and to identify the specific biological mechanisms of action.

Generate clinical proof of principle that novel approaches are beneficial either alone or in combination with existing therapies for the treatment of cancer patients.

Advocate findings in order to implement these approaches, improve the standard of care for patients, and contribute to a more sustainable healthcare system.